Industries > Pharma > Geriatric Medicines Market Report 2021-2031
Geriatric Medicines Market Report 2021-2031
By Therapeutic Category (Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor, Anticoagulant, Antipsychotic and Antidepressant, and Others), By Condition (Cardiovascular, Arthritis, Diabetes, Neurological, Cancer, Osteoporosis, Respiratory, and Others) By Drug Type (Generic Drugs, and Branded Drugs), By Form (Tablet, Capsules, Ointment, Gel, Lotion, Others), By Route of Administration (Oral, Topical, Intravenous, Others), By Mode of Prescription (OTC, and Prescribed), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis
Geriatric Medicines Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Geriatric Medicines is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 280+ page report provides 550+ tables and 540+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Geriatric Medicines Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Therapeutic Category
• Analgesic
• Antihypertensive
• Statins
• Antidiabetic
• Proton Pump Inhibitor
• Anticoagulant
• Antipsychotic and Antidepressant
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Condition
• Cardiovascular
• Arthritis
• Diabetes
• Neurological
• Cancer
• Osteoporosis
• Respiratory
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Form
• Tablet
• Capsules
• Ointment
• Gel
• Lotion
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Drug Type
• Generic Drugs
• Branded Drugs
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Route of Administration
• Oral
• Topical
• Intravenous
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Mode of Prescription
• OTC
• Prescribed
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Geriatric Medicines Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Geriatric Medicines Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Geriatric Medicines Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Geriatric Medicines Market report helps you
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Geriatric Medicines Market, with forecasts for Get our report today Geriatric Medicines Market Forecast 2021-2031: By Therapeutic Category, Condition, Drug Type, Form, Route of Administration, Mode of Prescription, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Geriatric Medicines market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Geriatric Medicines Market. Some of the company’s profiled in this report include
• Pfizer, Inc.
• Merck & Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Novartis AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Abbott Laboratories
• Boehringer Ingelheim GmbH
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Geriatric Medicines Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Geriatric Medicines Market Report 2021-2031: By Therapeutic Category (Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor, Anticoagulant, Antipsychotic and Antidepressant, and Others), By Condition (Cardiovascular, Arthritis, Diabetes, Neurological, Cancer, Osteoporosis, Respiratory, and Others) By Drug Type (Generic Drugs, and Branded Drugs), By Form (Tablet, Capsules, Ointment, Gel, Lotion, Others), By Route of Administration (Oral, Topical, Intravenous, Others), By Mode of Prescription (OTC, and Prescribed), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Geriatric Medicines Market
2.1. Geriatric Medicines Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Geriatric Medicines Market Overview
3.1. Global Geriatric Medicines Market Size and Forecast By Region
3.2. Global Geriatric Medicines Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing geriatric population around the world
3.3.1.2. Increasing prevalence of chronic diseases
3.3.1.3. Availability of reimbursement in developing nations
3.3.1.4. Increasing strategic initiatives in geriatric medicines market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.2.3. Product recall
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure and advance healthcare facility
3.3.3.2. Increasing therapeutic advancement in geriatric medicines
3.3.4. Challenges
3.3.4.1. Availability of alternatives
3.3.4.2. Side effects associated with geriatric medicines
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Geriatric Medicines Market Analysis and Forecast 2021-2031, By Therapeutic Category (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Analgesic
4.1.1.1. Analgesic market size and forecast, 2021-2031 (USD Million)
4.1.2. Antihypertensive
4.1.2.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.3. Statins
4.1.3.1. Statins market size and forecast, 2021-2031 (USD Million)
4.1.4. Antidiabetic
4.1.4.1. Antidiabetic market size and forecast, 2021-2031 (USD Million)
4.1.5. Proton Pump Inhibitor
4.1.5.1. Proton Pump Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.6. Anticoagulant
4.1.6.1. Anticoagulant market size and forecast, 2021-2031 (USD Million)
4.1.7. Antipsychotic and Antidepressant
4.1.7.1. Antipsychotic and Antidepressant market size and forecast, 2021-2031 (USD Million)
4.1.8. Others
4.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Condition (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Cardiovascular
5.1.1.1. Cardiovascular market size and forecast, 2021-2031 (USD Million)
5.1.2. Arthritis
5.1.2.1. Arthritis market size and forecast, 2021-2031 (USD Million)
5.1.3. Diabetes
5.1.3.1. Diabetes market size and forecast, 2021-2031 (USD Million)
5.1.4. Neurological
5.1.4.1. Neurological market size and forecast, 2021-2031 (USD Million)
5.1.5. Cancer
5.1.5.1. Cancer market size and forecast, 2021-2031 (USD Million)
5.1.6. Osteoporosis
5.1.6.1. Osteoporosis market size and forecast, 2021-2031 (USD Million)
5.1.7. Respiratory
5.1.7.1. Respiratory market size and forecast, 2021-2031 (USD Million)
5.1.8. Others
5.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Tablet
6.1.1.1. Tablet market size and forecast, 2021-2031 (USD Million)
6.1.2. Capsules
6.1.2.1. Capsules market size and forecast, 2021-2031 (USD Million)
6.1.3. Ointment
6.1.3.1. Ointment market size and forecast, 2021-2031 (USD Million)
6.1.4. Gel
6.1.4.1. Gel market size and forecast, 2021-2031 (USD Million)
6.1.5. Lotion
6.1.5.1. Lotion market size and forecast, 2021-2031 (USD Million)
6.1.6. Others
6.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
7. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Mode of Prescription (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. OTC
8.1.1.1. OTC market size and forecast, 2021-2031 (USD Million)
8.1.2. Prescribed
8.1.2.1. Prescribed market size and forecast, 2021-2031 (USD Million)
9. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Oral
9.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
9.1.2. Topical
9.1.2.1. Topical market size and forecast, 2021-2031 (USD Million)
9.1.3. Intravenous
9.1.3.1. Intravenous market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.3. Online Pharmacies
11.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
12. North America Geriatric Medicines Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Geriatric Medicines Market Size and Forecast By Therapeutic Category
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Geriatric Medicines Market Size and Forecast By Condition
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Geriatric Medicines Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Geriatric Medicines Market Size and Forecast By Form
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Geriatric Medicines Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Geriatric Medicines Market Size and Forecast By Mode of Prescription
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Geriatric Medicines Market Size and Forecast By End-User
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. North America Geriatric Medicines Market Size and Forecast By Distribution Channel
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. U.S. Geriatric Medicines Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Canada Geriatric Medicines Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Europe Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Geriatric Medicines Market Size and Forecast By Therapeutic Category
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Geriatric Medicines Market Size and Forecast By Condition
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Geriatric Medicines Market Size and Forecast By Form
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Geriatric Medicines Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Geriatric Medicines Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Geriatric Medicines Market Size and Forecast By Mode of Prescription
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Geriatric Medicines Market Size and Forecast By End-User
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Europe Geriatric Medicines Market Size and Forecast By Distribution Channel
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. UK Geriatric Medicines Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Germany Geriatric Medicines Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. France Geriatric Medicines Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
13.13. Rest of Europe Geriatric Medicines Market
13.13.1.1. XX Driving/Opportunity Factor
13.13.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Geriatric Medicines Market Size and Forecast By Therapeutic Category
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Geriatric Medicines Market Size and Forecast By Condition
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Geriatric Medicines Market Size and Forecast By Form
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Geriatric Medicines Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Geriatric Medicines Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Geriatric Medicines Market Size and Forecast By Mode of Prescription
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Geriatric Medicines Market Size and Forecast By End-User
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. Asia-Pacific Geriatric Medicines Market Size and Forecast By Distribution Channel
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. China Geriatric Medicines Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. India Geriatric Medicines Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Japan Geriatric Medicines Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
14.13. Rest of Asia Pacific Geriatric Medicines Market
14.13.1.1. XX Driving/Opportunity Factor
14.13.1.2. XX Driving/Opportunity Factor
15. Latin America Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Geriatric Medicines Market Size and Forecast By Therapeutic Category
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Geriatric Medicines Market Size and Forecast By Condition
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Geriatric Medicines Market Size and Forecast By Form
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Geriatric Medicines Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Geriatric Medicines Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Geriatric Medicines Market Size and Forecast By Mode of Prescription
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Geriatric Medicines Market Size and Forecast By End-User
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. Latin America Geriatric Medicines Market Size and Forecast By Distribution Channel
15.10. Brazil Geriatric Medicines Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Mexico Geriatric Medicines Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
15.12. Rest of Latin America Geriatric Medicines Market
15.12.1.1. XX Driving/Opportunity Factor
15.12.1.2. XX Driving/Opportunity Factor
16. MEA Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Geriatric Medicines Market Size and Forecast By Therapeutic Category
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Geriatric Medicines Market Size and Forecast By Condition
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Geriatric Medicines Market Size and Forecast By Form
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Geriatric Medicines Market Size and Forecast By Drug Type
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Geriatric Medicines Market Size and Forecast By Route of Administration
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Geriatric Medicines Market Size and Forecast By Mode of Prescription
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Geriatric Medicines Market Size and Forecast By End-User
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. MEA Geriatric Medicines Market Size and Forecast By Distribution Channel
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. GCC Geriatric Medicines Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. South Africa Geriatric Medicines Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
16.12. Rest of MEA Geriatric Medicines Market
16.12.1.1. XX Driving/Opportunity Factor
16.12.1.2. XX Driving/Opportunity Factor
17. Companies in the Geriatric Medicines Market
17.1. Pfizer Inc.
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. Merck & Co., Inc.
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. Novartis AG
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. AstraZeneca
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. Bristol-Myers Squibb Company
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Sanofi S.A.
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. GlaxoSmithKline plc
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. Eli Lilly and Company
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Abbott Laboratories
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Boehringer Ingelheim GmbH
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Geriatric Medicines Market Drivers & Restraints 2021
Table 7. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. OTC h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 148. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 149. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 150. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 151. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 152. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 153. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 154. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 155. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 156. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 157. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 158. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 159. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 160. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 161. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 162. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 163. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 164. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 165. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 166. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 167. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 171. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 173. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 174. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 175. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 176. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 177. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 178. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 179. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 180. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 181. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 182. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 183. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 184. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 185. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 186. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 187. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 188. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 189. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 190. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 191. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 192. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 193. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 194. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 195. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 196. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 198. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 199. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 200. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 201. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 202. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 203. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 204. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 205. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 206. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 207. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 208. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 209. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 210. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 211. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 212. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 213. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 214. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 215. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 216. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 217. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 218. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 219. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 220. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 221. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 222. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 223. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 224. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 225. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 226. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 227. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 228. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 229. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 230. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 231. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 232. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 233. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 234. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 235. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 236. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 237. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 238. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 239. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 240. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 241. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 242. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 243. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 244. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 245. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 246. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 247. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 248. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 249. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 250. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 251. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 252. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 253. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 254. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 255. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 256. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 257. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 258. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 259. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 260. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 261. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 262. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 263. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 264. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 265. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 266. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 267. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 268. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 269. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 270. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 271. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 272. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 273. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 274. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 275. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 276. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 277. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 278. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 279. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 280. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 281. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 282. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 283. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 284. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 285. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 286. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 287. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 288. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 289. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 290. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 291. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 292. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 293. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 294. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 295. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 296. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 297. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 298. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 299. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 300. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 301. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 302. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 303. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 304. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 305. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 306. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 307. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 308. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 309. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 310. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 311. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 312. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 313. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 314. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 315. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 316. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 317. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 318. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 319. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 320. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 321. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 322. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 323. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 324. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 325. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 326. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 327. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 328. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 329. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 330. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 331. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 332. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 333. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 334. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 335. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 336. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 337. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 338. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 339. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 340. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 341. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 342. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 343. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 344. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 345. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 346. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 347. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 348. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 349. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 350. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 351. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 352. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 353. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 354. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 355. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 356. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 357. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 358. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 359. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 360. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 361. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 362. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 363. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 364. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 365. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 366. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 367. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 368. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 369. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 370. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 371. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 372. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 373. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 374. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 375. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 376. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 377. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 378. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 379. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 380. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 381. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 382. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 383. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 384. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 385. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 386. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 387. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 388. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 389. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 390. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 391. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 392. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 393. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 394. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 395. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 396. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 397. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 398. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 399. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 400. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 401. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 402. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 403. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 404. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 405. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 406. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 407. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 408. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 409. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 410. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 411. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 412. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 413. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 414. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 415. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 416. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 417. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 418. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 419. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 420. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 421. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 422. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 423. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 424. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 425. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 426. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 427. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 428. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 429. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 430. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 431. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 432. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 433. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 434. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 435. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 436. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 437. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 438. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 439. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 440. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 441. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 442. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 443. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 444. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 445. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 446. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 447. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 448. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 449. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 450. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 451. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 452. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 453. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 454. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 455. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 456. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 457. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 458. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 459. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 460. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 461. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 462. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 463. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 464. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 465. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 466. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 467. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 468. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 469. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 470. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 471. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 472. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 473. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 474. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 475. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 476. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 477. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 478. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 479. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 480. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 481. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 482. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 483. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 484. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 485. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 486. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 487. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 488. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 489. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 490. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 491. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 492. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 493. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 494. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 495. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 496. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 497. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 498. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 499. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 500. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 501. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 502. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 503. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 504. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 505. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 506. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 507. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 508. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 509. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 510. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 511. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 512. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 513. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 514. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 515. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 516. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 517. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 518. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 519. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 520. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 521. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 522. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 523. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 524. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 525. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 526. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 527. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 528. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 529. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 530. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 531. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 532. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 533. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 534. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 535. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 536. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 537. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 538. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 539. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 540. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 541. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 542. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 543. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 544. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 545. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 546. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 547. Leading 10 Geriatric Medicines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 548. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 549. Pfizer Inc. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 550. Merck & Co., Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 551. Merck & Co., Inc. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 552. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 553. Novartis AG.Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 554. AstraZeneca Profile 2019 (CEO, HQ, Founded, Website)
Table 555. AstraZeneca Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 556. Bristol-Myers Squibb Company Profile 2019 (CEO, HQ, Founded, Website)
Table 557. Bristol-Myers Squibb Company Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 558. Sanofi S.A. Profile 2019 (CEO, HQ, Founded, Website)
Table 559. Sanofi S.A. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 560. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Table 561. GlaxoSmithKline plc Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 562. Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 563. Eli Lilly and Company Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 564. Abbott Laboratories Profile 2019 (CEO, HQ, Founded, Website)
Table 565. Abbott Laboratories Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 566. Boehringer Ingelheim GmbH Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 567. Boehringer Ingelheim GmbH Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 568. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 569. AstraZeneca plc Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 570. Other Companies Involved in the Geriatric Medicines Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Geriatric Medicines Market Drivers & Restraints 2021
Figure 7. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. OTC h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 148. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 149. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 150. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 151. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 152. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 153. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 154. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 155. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 156. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 157. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 158. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 159. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 160. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 161. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 162. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 163. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 164. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 165. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 166. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 167. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 171. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 173. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 174. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 175. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 176. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 177. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 178. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 179. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 180. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 181. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 182. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 183. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 184. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 185. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 186. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 187. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 188. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 189. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 190. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 191. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 192. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 193. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 194. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 195. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 196. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 198. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 199. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 200. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 201. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 202. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 203. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 204. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 205. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 206. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 207. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 208. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 209. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 210. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 211. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 212. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 213. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 214. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 215. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 216. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 217. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 218. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 219. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 220. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 221. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 222. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 223. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 224. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 225. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 226. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 227. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 228. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 229. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 230. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 231. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 232. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 233. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 234. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 235. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 236. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 237. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 238. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 239. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 240. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 241. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 242. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 243. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 244. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 245. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 246. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 247. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 248. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 249. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 250. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 251. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 252. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 253. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 254. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 255. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 256. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 257. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 258. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 259. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 260. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 261. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 262. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 263. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 264. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 265. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 266. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 267. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 268. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 269. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 270. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 271. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 272. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 273. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 274. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 275. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 276. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 277. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 278. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 279. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 280. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 281. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 282. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 283. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 284. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 285. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 286. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 287. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 288. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 289. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 290. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 291. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 292. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 293. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 294. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 295. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 296. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 297. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 298. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 299. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 300. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 301. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 302. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 303. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 304. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 305. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 306. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 307. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 308. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 309. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 310. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 311. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 312. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 313. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 314. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 315. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 316. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 317. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 318. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 319. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 320. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 321. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 322. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 323. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 324. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 325. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 326. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 327. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 328. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 329. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 330. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 331. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 332. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 333. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 334. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 335. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 336. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 337. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 338. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 339. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 340. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 341. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 342. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 343. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 344. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 345. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 346. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 347. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 348. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 349. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 350. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 351. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 352. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 353. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 354. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 355. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 356. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 357. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 358. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 359. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 360. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 361. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 362. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 363. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 364. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 365. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 366. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 367. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 368. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 369. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 370. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 371. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 372. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 373. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 374. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 375. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 376. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 377. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 378. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 379. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 380. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 381. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 382. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 383. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 384. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 385. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 386. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 387. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 388. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 389. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 390. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 391. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 392. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 393. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 394. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 395. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 396. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 397. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 398. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 399. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 400. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 401. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 402. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 403. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 404. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 405. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 406. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 407. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 408. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 409. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 410. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 411. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 412. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 413. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 414. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 415. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 416. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 417. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 418. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 419. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 420. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 421. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 422. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 423. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 424. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 425. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 426. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 427. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 428. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 429. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 430. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 431. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 432. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 433. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 434. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 435. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 436. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 437. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 438. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 439. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 440. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 441. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 442. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 443. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 444. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 445. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 446. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 447. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 448. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 449. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 450. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 451. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 452. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 453. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 454. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 455. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 456. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 457. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 458. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 459. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 460. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 461. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 462. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 463. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 464. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 465. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 466. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 467. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 468. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 469. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 470. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 471. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 472. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 473. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 474. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 475. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 476. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 477. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 478. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 479. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 480. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 481. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 482. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 483. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 484. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 485. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 486. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 487. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 488. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 489. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 490. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 491. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 492. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 493. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 494. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 495. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 496. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 497. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 498. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 499. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 500. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 501. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 502. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 503. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 504. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 505. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 506. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 507. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 508. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 509. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 510. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 511. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 512. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 513. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 514. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 515. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 516. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 517. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 518. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 519. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 520. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 521. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 522. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 523. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 524. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 525. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 526. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 527. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 528. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 529. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 530. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 531. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 532. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 533. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 534. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 535. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 536. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 537. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 538. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 539. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 540. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 541. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 542. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 543. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 544. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 545. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 546. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 547. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Geriatric Medicines Market
2.1. Geriatric Medicines Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Geriatric Medicines Market Overview
3.1. Global Geriatric Medicines Market Size and Forecast By Region
3.2. Global Geriatric Medicines Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing geriatric population around the world
3.3.1.2. Increasing prevalence of chronic diseases
3.3.1.3. Availability of reimbursement in developing nations
3.3.1.4. Increasing strategic initiatives in geriatric medicines market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.2.3. Product recall
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure and advance healthcare facility
3.3.3.2. Increasing therapeutic advancement in geriatric medicines
3.3.4. Challenges
3.3.4.1. Availability of alternatives
3.3.4.2. Side effects associated with geriatric medicines
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Geriatric Medicines Market Analysis and Forecast 2021-2031, By Therapeutic Category (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Analgesic
4.1.1.1. Analgesic market size and forecast, 2021-2031 (USD Million)
4.1.2. Antihypertensive
4.1.2.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.3. Statins
4.1.3.1. Statins market size and forecast, 2021-2031 (USD Million)
4.1.4. Antidiabetic
4.1.4.1. Antidiabetic market size and forecast, 2021-2031 (USD Million)
4.1.5. Proton Pump Inhibitor
4.1.5.1. Proton Pump Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.6. Anticoagulant
4.1.6.1. Anticoagulant market size and forecast, 2021-2031 (USD Million)
4.1.7. Antipsychotic and Antidepressant
4.1.7.1. Antipsychotic and Antidepressant market size and forecast, 2021-2031 (USD Million)
4.1.8. Others
4.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Condition (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Cardiovascular
5.1.1.1. Cardiovascular market size and forecast, 2021-2031 (USD Million)
5.1.2. Arthritis
5.1.2.1. Arthritis market size and forecast, 2021-2031 (USD Million)
5.1.3. Diabetes
5.1.3.1. Diabetes market size and forecast, 2021-2031 (USD Million)
5.1.4. Neurological
5.1.4.1. Neurological market size and forecast, 2021-2031 (USD Million)
5.1.5. Cancer
5.1.5.1. Cancer market size and forecast, 2021-2031 (USD Million)
5.1.6. Osteoporosis
5.1.6.1. Osteoporosis market size and forecast, 2021-2031 (USD Million)
5.1.7. Respiratory
5.1.7.1. Respiratory market size and forecast, 2021-2031 (USD Million)
5.1.8. Others
5.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Tablet
6.1.1.1. Tablet market size and forecast, 2021-2031 (USD Million)
6.1.2. Capsules
6.1.2.1. Capsules market size and forecast, 2021-2031 (USD Million)
6.1.3. Ointment
6.1.3.1. Ointment market size and forecast, 2021-2031 (USD Million)
6.1.4. Gel
6.1.4.1. Gel market size and forecast, 2021-2031 (USD Million)
6.1.5. Lotion
6.1.5.1. Lotion market size and forecast, 2021-2031 (USD Million)
6.1.6. Others
6.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
7. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Mode of Prescription (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. OTC
8.1.1.1. OTC market size and forecast, 2021-2031 (USD Million)
8.1.2. Prescribed
8.1.2.1. Prescribed market size and forecast, 2021-2031 (USD Million)
9. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Oral
9.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
9.1.2. Topical
9.1.2.1. Topical market size and forecast, 2021-2031 (USD Million)
9.1.3. Intravenous
9.1.3.1. Intravenous market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. Global Geriatric Medicines Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.3. Online Pharmacies
11.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
12. North America Geriatric Medicines Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Geriatric Medicines Market Size and Forecast By Therapeutic Category
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Geriatric Medicines Market Size and Forecast By Condition
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Geriatric Medicines Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Geriatric Medicines Market Size and Forecast By Form
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Geriatric Medicines Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Geriatric Medicines Market Size and Forecast By Mode of Prescription
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Geriatric Medicines Market Size and Forecast By End-User
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. North America Geriatric Medicines Market Size and Forecast By Distribution Channel
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. U.S. Geriatric Medicines Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Canada Geriatric Medicines Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Europe Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Geriatric Medicines Market Size and Forecast By Therapeutic Category
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Geriatric Medicines Market Size and Forecast By Condition
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Geriatric Medicines Market Size and Forecast By Form
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Geriatric Medicines Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Geriatric Medicines Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Geriatric Medicines Market Size and Forecast By Mode of Prescription
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Geriatric Medicines Market Size and Forecast By End-User
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Europe Geriatric Medicines Market Size and Forecast By Distribution Channel
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. UK Geriatric Medicines Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Germany Geriatric Medicines Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. France Geriatric Medicines Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
13.13. Rest of Europe Geriatric Medicines Market
13.13.1.1. XX Driving/Opportunity Factor
13.13.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Geriatric Medicines Market Size and Forecast By Therapeutic Category
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Geriatric Medicines Market Size and Forecast By Condition
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Geriatric Medicines Market Size and Forecast By Form
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Geriatric Medicines Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Geriatric Medicines Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Geriatric Medicines Market Size and Forecast By Mode of Prescription
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Geriatric Medicines Market Size and Forecast By End-User
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. Asia-Pacific Geriatric Medicines Market Size and Forecast By Distribution Channel
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. China Geriatric Medicines Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. India Geriatric Medicines Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Japan Geriatric Medicines Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
14.13. Rest of Asia Pacific Geriatric Medicines Market
14.13.1.1. XX Driving/Opportunity Factor
14.13.1.2. XX Driving/Opportunity Factor
15. Latin America Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Geriatric Medicines Market Size and Forecast By Therapeutic Category
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Geriatric Medicines Market Size and Forecast By Condition
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Geriatric Medicines Market Size and Forecast By Form
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Geriatric Medicines Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Geriatric Medicines Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Geriatric Medicines Market Size and Forecast By Mode of Prescription
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Geriatric Medicines Market Size and Forecast By End-User
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. Latin America Geriatric Medicines Market Size and Forecast By Distribution Channel
15.10. Brazil Geriatric Medicines Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Mexico Geriatric Medicines Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
15.12. Rest of Latin America Geriatric Medicines Market
15.12.1.1. XX Driving/Opportunity Factor
15.12.1.2. XX Driving/Opportunity Factor
16. MEA Geriatric Medicines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Geriatric Medicines Market Size and Forecast By Therapeutic Category
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Geriatric Medicines Market Size and Forecast By Condition
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Geriatric Medicines Market Size and Forecast By Form
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Geriatric Medicines Market Size and Forecast By Drug Type
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Geriatric Medicines Market Size and Forecast By Route of Administration
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Geriatric Medicines Market Size and Forecast By Mode of Prescription
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Geriatric Medicines Market Size and Forecast By End-User
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. MEA Geriatric Medicines Market Size and Forecast By Distribution Channel
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. GCC Geriatric Medicines Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. South Africa Geriatric Medicines Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
16.12. Rest of MEA Geriatric Medicines Market
16.12.1.1. XX Driving/Opportunity Factor
16.12.1.2. XX Driving/Opportunity Factor
17. Companies in the Geriatric Medicines Market
17.1. Pfizer Inc.
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. Merck & Co., Inc.
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. Novartis AG
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. AstraZeneca
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. Bristol-Myers Squibb Company
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Sanofi S.A.
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. GlaxoSmithKline plc
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. Eli Lilly and Company
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Abbott Laboratories
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Boehringer Ingelheim GmbH
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Geriatric Medicines Market Drivers & Restraints 2021
Table 7. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. OTC h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 148. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 149. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 150. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 151. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 152. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 153. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 154. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 155. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 156. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 157. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 158. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 159. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 160. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 161. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 162. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 163. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 164. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 165. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 166. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 167. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 171. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 173. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 174. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 175. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 176. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 177. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 178. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 179. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 180. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 181. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 182. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 183. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 184. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 185. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 186. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 187. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 188. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 189. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 190. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 191. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 192. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 193. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 194. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 195. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 196. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 198. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 199. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 200. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 201. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 202. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 203. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 204. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 205. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 206. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 207. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 208. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 209. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 210. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 211. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 212. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 213. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 214. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 215. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 216. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 217. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 218. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 219. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 220. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 221. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 222. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 223. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 224. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 225. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 226. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 227. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 228. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 229. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 230. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 231. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 232. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 233. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 234. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 235. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 236. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 237. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 238. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 239. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 240. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 241. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 242. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 243. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 244. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 245. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 246. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 247. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 248. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 249. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 250. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 251. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 252. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 253. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 254. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 255. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 256. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 257. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 258. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 259. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 260. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 261. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 262. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 263. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 264. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 265. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 266. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 267. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 268. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 269. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 270. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 271. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 272. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 273. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 274. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 275. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 276. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 277. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 278. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 279. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 280. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 281. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 282. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 283. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 284. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 285. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 286. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 287. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 288. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 289. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 290. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 291. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 292. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 293. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 294. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 295. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 296. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 297. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 298. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 299. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 300. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 301. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 302. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 303. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 304. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 305. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 306. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 307. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 308. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 309. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 310. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 311. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 312. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 313. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 314. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 315. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 316. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 317. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 318. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 319. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 320. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 321. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 322. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 323. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 324. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 325. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 326. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 327. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 328. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 329. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 330. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 331. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 332. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 333. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 334. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 335. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 336. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 337. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 338. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 339. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 340. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 341. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 342. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 343. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 344. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 345. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 346. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 347. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 348. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 349. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 350. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 351. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 352. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 353. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 354. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 355. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 356. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 357. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 358. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 359. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 360. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 361. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 362. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 363. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 364. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 365. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 366. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 367. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 368. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 369. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 370. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 371. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 372. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 373. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 374. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 375. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 376. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 377. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 378. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 379. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 380. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 381. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 382. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 383. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 384. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 385. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 386. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 387. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 388. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 389. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 390. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 391. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 392. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 393. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 394. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 395. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 396. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 397. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 398. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 399. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 400. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 401. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 402. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 403. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 404. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 405. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 406. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 407. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 408. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 409. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 410. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 411. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 412. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 413. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 414. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 415. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 416. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 417. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 418. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 419. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 420. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 421. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 422. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 423. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 424. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 425. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 426. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 427. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 428. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 429. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 430. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 431. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 432. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 433. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 434. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 435. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 436. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 437. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 438. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 439. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 440. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 441. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 442. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 443. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 444. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 445. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 446. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 447. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 448. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 449. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 450. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 451. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 452. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 453. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 454. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 455. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 456. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 457. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 458. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 459. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 460. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 461. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 462. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 463. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 464. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 465. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 466. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 467. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 468. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 469. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 470. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 471. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 472. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 473. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 474. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 475. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 476. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 477. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 478. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 479. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 480. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 481. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 482. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 483. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 484. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 485. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 486. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 487. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 488. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 489. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 490. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 491. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 492. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 493. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 494. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 495. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 496. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 497. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 498. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 499. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 500. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 501. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 502. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 503. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 504. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 505. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 506. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 507. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 508. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 509. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 510. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 511. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 512. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 513. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 514. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 515. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 516. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 517. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 518. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 519. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 520. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 521. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 522. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 523. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 524. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 525. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 526. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 527. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 528. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 529. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 530. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 531. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 532. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 533. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 534. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 535. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 536. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 537. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 538. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 539. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 540. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 541. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 542. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 543. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 544. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 545. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 546. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 547. Leading 10 Geriatric Medicines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 548. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 549. Pfizer Inc. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 550. Merck & Co., Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 551. Merck & Co., Inc. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 552. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 553. Novartis AG.Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 554. AstraZeneca Profile 2019 (CEO, HQ, Founded, Website)
Table 555. AstraZeneca Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 556. Bristol-Myers Squibb Company Profile 2019 (CEO, HQ, Founded, Website)
Table 557. Bristol-Myers Squibb Company Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 558. Sanofi S.A. Profile 2019 (CEO, HQ, Founded, Website)
Table 559. Sanofi S.A. Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 560. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Table 561. GlaxoSmithKline plc Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 562. Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 563. Eli Lilly and Company Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 564. Abbott Laboratories Profile 2019 (CEO, HQ, Founded, Website)
Table 565. Abbott Laboratories Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 566. Boehringer Ingelheim GmbH Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 567. Boehringer Ingelheim GmbH Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 568. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 569. AstraZeneca plc Geriatric Medicines Product Offering (Segment, Product Offerings)
Table 570. Other Companies Involved in the Geriatric Medicines Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Geriatric Medicines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Geriatric Medicines Market Drivers & Restraints 2021
Figure 7. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Statins Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antidiabetic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Proton Pump Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Anticoagulant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Antipsychotic and Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Geriatric Medicines Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Cardiovascular Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Arthritis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Diabetes Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Neurological Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Cancer Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Osteoporosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Respiratory Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. OTC Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. OTC h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Prescribed Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Geriatric Medicines Market Forecast By Form 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Tablet Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Capsules Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Ointment Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Gel Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Lotion Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 146. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 148. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 149. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 150. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 151. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 152. Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 153. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 154. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 155. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 156. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 157. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 158. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 159. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 160. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 161. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 162. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 163. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 164. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 165. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 166. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 167. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 171. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 173. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 174. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 175. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 176. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 177. Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 178. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 179. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 180. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 181. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 182. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 183. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 184. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 185. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 186. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 187. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 188. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 189. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 190. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 191. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 192. Intravenous Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 193. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 194. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 195. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 196. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 198. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 199. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 200. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 201. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 202. Geriatric Medicines Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 203. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 204. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 205. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 206. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 207. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 208. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 209. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 210. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 211. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 212. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 213. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 214. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 215. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 216. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 217. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 218. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 219. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 220. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 221. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 222. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 223. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 224. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 225. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 226. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 227. Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 228. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 229. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 230. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 231. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 232. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 233. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 234. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 235. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 236. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 237. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 238. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 239. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 240. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 241. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 242. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 243. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 244. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 245. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 246. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 247. North America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 248. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 249. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 250. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 251. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 252. North America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 253. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 254. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 255. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 256. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 257. North America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 258. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 259. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 260. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 261. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 262. North America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 263. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 264. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 265. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 266. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 267. North America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 268. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 269. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 270. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 271. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 272. North America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 273. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 274. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 275. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 276. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 277. North America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 278. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 279. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 280. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 281. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 282. North America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 283. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 284. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 285. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 286. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 287. North America Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 288. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 289. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 290. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 291. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 292. US Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 293. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 294. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 295. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 296. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 297. Canada Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 298. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 299. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 300. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 301. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 302. Europe Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 303. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 304. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 305. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 306. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 307. Europe Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 308. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 309. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 310. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 311. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 312. Europe Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 313. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 314. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 315. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 316. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 317. Europe Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 318. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 319. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 320. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 321. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 322. Europe Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 323. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 324. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 325. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 326. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 327. Europe Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 328. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 329. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 330. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 331. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 332. Europe Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 333. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 334. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 335. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 336. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 337. Europe Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 338. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 339. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 340. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 341. Europe Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 342. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 343. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 344. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 345. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 346. UK Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 347. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 348. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 349. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 350. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 351. Germany Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 352. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 353. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 354. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 355. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 356. France Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 357. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 358. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 359. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 360. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 361. Rest of Europe Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 362. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 363. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 364. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 365. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 366. Asia Pacific Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 367. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 368. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 369. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 370. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 371. Asia Pacific Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 372. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 373. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 374. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 375. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 376. Asia Pacific Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 377. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 378. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 379. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 380. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 381. Asia Pacific Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 382. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 383. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 384. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 385. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 386. Asia Pacific Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 387. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 388. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 389. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 390. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 391. Asia Pacific Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 392. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 393. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 394. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 395. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 396. Asia Pacific Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 397. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 398. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 399. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 400. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 401. Asia Pacific Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 402. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 403. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 404. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 405. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 406. Asia Pacific Geriatric Medicines Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 407. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 408. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 409. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 410. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 411. China Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 412. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 413. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 414. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 415. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 416. India Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 417. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 418. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 419. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 420. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 421. Japan Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 422. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 423. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 424. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 425. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 426. RoAPAC Geriatric Medicines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 427. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 428. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 429. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 430. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 431. Middle East Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 432. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 433. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 434. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 435. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 436. Middle East Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 437. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 438. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 439. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 440. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 441. Middle East Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 442. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 443. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 444. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 445. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 446. Middle East Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 447. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 448. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 449. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 450. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 451. Middle East Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 452. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 453. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 454. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 455. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 456. Middle East Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 457. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 458. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 459. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 460. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 461. Middle East Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 462. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 463. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 464. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 465. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 466. Middle East Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 467. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 468. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 469. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 470. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 471. Latin America Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 472. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 473. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 474. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 475. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 476. Latin America Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 477. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 478. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 479. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 480. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 481. Latin America Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 482. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 483. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 484. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 485. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 486. Latin America Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 487. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 488. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 489. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 490. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 491. Latin America Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 492. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 493. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 494. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 495. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 496. Latin America Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 497. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 498. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 499. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 500. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 501. Latin America Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 502. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 503. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 504. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 505. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 506. Latin America Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 507. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 508. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 509. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 510. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 511. Africa Geriatric Medicines Market Forecast By Therapeutic Category 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 512. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 513. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 514. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 515. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 516. Africa Geriatric Medicines Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 517. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 518. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 519. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 520. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 521. Africa Geriatric Medicines Market Forecast By Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 522. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 523. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 524. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 525. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 526. Africa Geriatric Medicines Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 527. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 528. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 529. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 530. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 531. Africa Geriatric Medicines Market Forecast By Mode of Prescription 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 532. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 533. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 534. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 535. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 536. Africa Geriatric Medicines Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 537. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 538. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 539. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 540. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 541. Africa Geriatric Medicines Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 542. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 543. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 544. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 545. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 546. Africa Geriatric Medicines Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 547. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Pfizer, Inc.
2. Merck & Co., Inc.
3. AstraZeneca
4. Bristol-Myers Squibb Company
5. Novartis AG
6. Sanofi S.A.
7. GlaxoSmithKline plc
8. Eli Lilly and Company
9. Abbott Laboratories
10. Boehringer Ingelheim GmbH
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
1. Pfizer, Inc.
2. Merck & Co., Inc.
3. AstraZeneca
4. Bristol-Myers Squibb Company
5. Novartis AG
6. Sanofi S.A.
7. GlaxoSmithKline plc
8. Eli Lilly and Company
9. Abbott Laboratories
10. Boehringer Ingelheim GmbH
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. AbbVie
3. Achaogen
4. Actavis
5. Actelion
6. Affinium Pharmaceutical
7. AiCuris GmbH & Co. KG
8. Alcon
9. Alkem Laboratories
10. Allergan
11. Allied Pharma
12. Apotex
13. APP Pharmaceuticals
14. Aptalis Pharma
15. Aquapharm Biodiscovery
16. Cempra Pharmaceuticals
17. Cipla
18. Claris Lifesciences
19. Cornerstone Biopharma
20. Cornerstone Therapeutics
21. Corona Remedies
22. Eli Lilly
23. Gate Pharma
24. Gilead Sciences
25. GlaxoSmithKline (GSK)
26. Glenmark
27. GlycoVaxyn
28. Hetero
29. Hikma Farmaceutica
30. Hi-Tech Pharma
31. Hospira
32. Macleod Pharmaceuticals
33. Microlabs
34. Nalneva
35. Novartis
36. Novexel
37. Paratek Pharmaceuticals
38. Pfizer
39. Ranbaxy
40. Roche
41. Sagent Pharmaceuticals
42. Sandoz
43. Sanofi
44. Sequella
45. Shanghai MengKe Pharmaceuticals
46. Shionogi
47. SHIONOGI Co., Ltd.
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
Download sample pages
Complete the form below to download your free sample pages for Geriatric Medicines Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Geriatric Medicines Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
Visiongain Publishes Stem Cell Therapy Contract Manufacturing Market Report 2023-2033
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
13 September 2023
Visiongain Publishes Immuno-Oncology Clinical Trials Market Report 2023-2033
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.
11 September 2023
